TIL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TI

Mkt Cap

$40.3M

Volume

24.53K

Next Earnings

November 12th

Loading chart

TI

TILInstil Bio, Inc. Common Stock

TIL

Pay with—

Available Balance0.00

TI

Mkt Cap

$40.1M

Volume

24.53K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateInstil Bio (Nasdaq: TIL) reported Q1 2026 results with a cash position of $74.7 million, sufficient to fund operations beyond 2027. The company is actively evaluating acquisition and in-licensing opportunities to build its pipeline. R&D expenses decreased to $0.7 million from $5.4 million year-over-year, while net loss per share improved to $0.62 from $4.32.GlobeNewswire Inc. · May 15, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of First Solar, Inc. - FSLRPomerantz LLP is investigating potential securities fraud claims on behalf of investors in First Solar, Instil Bio, and Corcept Therapeutics. First Solar's stock fell 10.29% on January 7, 2026, following a Jefferies downgrade to Hold due to lowered guidance, significant de-bookings, margin compression, and limited deployment opportunities expected in 2026.GlobeNewswire Inc. · Jan 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIOPomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar investigations were initiated for Instil Bio and Corcept Therapeutics.GlobeNewswire Inc. · Jan 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - ASTSPomerantz LLP is investigating potential securities fraud claims on behalf of investors in AST SpaceMobile, Instil Bio, and Corcept Therapeutics. The investigation into AST was triggered by a Scotiabank downgrade to Sell on January 7, 2026, citing competition from SpaceX's Starlink, slow customer adoption, and satellite launch delays. AST's stock fell 12.06% following the downgrade.GlobeNewswire Inc. · Jan 13, 2026

Instil Bio Posts Wider Loss in Q2Instil Bio reported a wider loss in Q2 2025, with Non-GAAP EPS of $(2.88), missing analyst expectations. The company increased R&D spending to $6.7 million and received FDA clearance for its lead drug candidate '2510, with plans to launch a U.S. clinical trial before year-end.The Motley Fool · Aug 13, 2025

Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightOver 180 companies are developing 250+ bispecific antibodies targeting complex chronic diseases like cancer and autoimmune disorders, with innovative dual-targeting molecules offering superior therapeutic precision and efficacy.GlobeNewswire Inc. · Jul 7, 2025

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramInstil Bio, a clinical-stage biopharmaceutical company, announced the addition of John Maraganore, Ph.D., to the Board of Directors of its subsidiary Axion Bio, which is developing a PD-L1xVEGF bispecific antibody for solid tumors.GlobeNewswire Inc. · Jun 11, 2025

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025Instil Bio and ImmuneOnco announced the progress of their Phase 2 trial of AXN-2510/IMM2510, a PD-L1xVEGF bispecific antibody, in combination with chemotherapy for first-line NSCLC in China. The trial is expected to complete enrollment in Q3 2025, with initial results anticipated in 2H 2025.GlobeNewswire Inc. · May 22, 2025

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateInstil Bio reported its Q1 2025 financial results, including ongoing enrollment of 1L NSCLC patients in a China trial of AXN-2510/IMM2510 in combination with chemotherapy, with initial data expected in 2H 2025. The company also plans to initiate a U.S. clinical study of the same combination in 1L NSCLC before the end of 2025.GlobeNewswire Inc. · May 13, 2025

Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway GloballyThe TIL Therapies Market is projected to grow from USD 87 million in 2024 to USD 5 billion by 2035, at a CAGR of 40%. Over 75 therapies are under development and more than 100 clinical trials are underway globally, with key players including Iovance Biotherapeutics, Bristol-Myers Squibb, and Instil Bio.GlobeNewswire Inc. · Apr 1, 2025

to start trading

TI

TILInstil Bio, Inc. Common Stock

TIL

Pay with—

Available Balance0.00

Your PositionYou don't own any TIL yet.

Related Tickers

Earnings